RankingsPricing
  1. US-listed companies
  2. Edwards Lifesciences Corp
  3. Financials
  4. Cash and cash equivalents

Edwards Lifesciences CorpEW

Market cap
$49.9B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 20243,059+166.45%
Dec 31, 20231,148+48.59%
Dec 31, 2022773-10.93%
Dec 31, 2021867-27.73%
Dec 31, 20201,200+1.79%
Dec 31, 20191,179+65.12%
Dec 31, 2018714-12.73%
Dec 31, 2017818-12.02%
Dec 31, 2016930+29.47%
Dec 31, 2015718+9.88%
Dec 31, 2014654+55.52%
Dec 31, 2013420+35.22%
Dec 31, 2012311+81.60%
Dec 31, 2011171-56.78%
Dec 31, 2010396

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)